# Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy

> **NCT04722133** · PHASE2 · COMPLETED · sponsor: **Yonsei University** · enrollment: 36 (actual)

## Conditions studied

- HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer

## Interventions

- **DRUG:** HERZUMA+mFOLFOX

## Key facts

- **NCT ID:** NCT04722133
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-23
- **Primary completion:** 2023-06-14
- **Final completion:** 2023-06-14
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04722133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04722133, "Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04722133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*